a possible treatment for malignant melanoma

Herpes simplex virus HSV1716 replicates in and kills melanoma tumour cells, suggesting a possible therapeutic use.

By | February 16, 2001

Malignant melanoma, the most serious form of skin cancer, is composed of cells derived from the foetal neural crests. Herpes simplex virus (HSV) is neurotropic virus and can therefore localise in melanoma cells. HSV variant 1716 replicates preferentially in human melanoma cell lines in vitro, causing cell lysis and death. On the basis of this mechanism, researchers from University of Glasgow suggest in a research letter to the Lancet, that HSV1716 could be used for the local treatment of human malignant melanoma.

In a preliminary study, Rona MacKie and colleagues tested the effects of intratumoral injection of HSV1716 into subcutaneous nodules of metastatic melanoma in five patients with advanced (stage 4) disease. For each patient, a test nodule was injected with103 pfu HSV1716, and a second nodule was injected with 1 ml sterile saline as a control. In one patient, flattening of previously palpable tumour nodules was seen 21 days after two direct injections of HSV1716. Nodules of all three patients who received two or more injections showed evidence of tumour necrosis (Lancet 2001, 357:525-526).

MacKie comments: "This pilot study shows that HSV1716 replicates in melanoma cells, causes tumour-cell death if in direct contact with the melanoma cells, and is not toxic. The results are sufficiently encouraging to continue with higher doses of HSV1716 in patients with metastatic melanoma."

Popular Now

  1. Can Young Stem Cells Make Older People Stronger?
  2. Thousands of Mutations Accumulate in the Human Brain Over a Lifetime
  3. Two Dozen House Republicans Do an About-Face on Tuition Tax
  4. CRISPR to Debut in Clinical Trials